undamentalytics Newsletter
Sign in

ADC Therapeutics SA balance sheet

At the end of fiscal 2025, ADC Therapeutics SA had total assets of $323m, total liabilities of $509m and shareholders' equity of −$186m. It held $261m in cash against $116m of debt: net cash of $146m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents326279251261219
Receivables7325202928
Inventory1216245
Total current assets435336291306262
Total assets491355322323279
Accounts payable121618913
Total current liabilities8268807086
Short-term debt——036
Total debt110113114116117
Total liabilities411503525509508
Shareholders' equity79−148−203−186−228
Net debt (negative = net cash)−217−166−137−146−102
Shares outstanding81m82m99m126m127m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: AAPG vs ADCTADCT vs PLXADCT vs BCYC

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from ADC Therapeutics SA's SEC filings (10-K and 10-Q), retrieved October 31, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to ADC Therapeutics SA.